18 June 2013
Keywords: recombinant, calcitonin, osteoporosis, unigene, presented, results, its
Article | 08 July 1996
- Unigene has presented results of its latest Phase I clinical trial
that demonstrates the efficacy at low doses of Fortical ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 July 1996
17 June 2013
© 2013 thepharmaletter.com